Sphingolipid De Novo Biosynthesis: A Rheostat of Cardiovascular Homeostasis

Trends Endocrinol Metab. 2016 Nov;27(11):807-819. doi: 10.1016/j.tem.2016.07.005. Epub 2016 Aug 22.

Abstract

Sphingolipids (SL) are both fundamental structural components of the eukaryotic membranes and signaling molecules that regulate a variety of biological functions. The highly-bioactive lipids, ceramide and sphingosine-1-phosphate, have emerged as important regulators of cardiovascular function in health and disease. In this review we discuss recent insights into the role of SLs, particularly ceramide and sphingosine-1-phosphate, in the pathophysiology of the cardiovascular system. We also highlight advances into the molecular mechanisms regulating serine palmitoyltransferase, the first and rate-limiting enzyme of de novo SL biosynthesis, with an emphasis on the recently discovered inhibitors of serine palmitoyltransferase, ORMDL and NOGO-B proteins. Understanding the molecular mechanisms regulating this biosynthetic pathway may lead to the development of novel therapeutic approaches for the treatment of cardiovascular diseases.

Keywords: Nogo-B; SPT; cardiovascular diseases; sphingolipids.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiovascular Diseases / metabolism*
  • Homeostasis
  • Humans
  • Lysophospholipids / metabolism
  • Nogo Proteins / metabolism
  • Sphingolipids / biosynthesis*
  • Sphingolipids / metabolism
  • Sphingosine / analogs & derivatives
  • Sphingosine / metabolism

Substances

  • Lysophospholipids
  • Nogo Proteins
  • Sphingolipids
  • sphingosine 1-phosphate
  • Sphingosine